18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting
 response to treatment. This study aimed to evaluate the ability of pretreatment positron
 emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the
 response to pyrotinib in patients with human epidermal growth factor receptor 2
 (HER2)-positive metastatic breast cancer (MBC).
Inclusion Criteria:

 -  Pathologically confirmed HER2 positive breast cancer

 -  Treated with Pyrotinib in the metastatic settings

 -  Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and
 capecitabine were included in this study

 Exclusion Criteria:

 -  Incomplete medical history

 -  Loss of follow up